Preventive treatment with mAbs targeting either TLR2 (T2.5) or TLR4 (1A6) caused a significant improvement in the survival rate during severe sepsis (Fig 1A) compared to the isotype control group, where 100% of the mice subjected to CLP succumbed within 24 hours. This evidence concerns the gene TLR4 and Sepsis.